Skip to content

Study · Animal study (in vivo) · mouse · 2014

12 results

GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.

Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L, Pinthus JH

Urologic oncology18 Sept 2014Cited by 67 (Europe PMC)

PMID25242517 (opens in a new tab)DOI10.1016/j.urolonc.2014.06.018 (opens in a new tab)PepBankPUB-25242517
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, degarelix decreased circulating testosterone, as did the other androgen deprivation modalities.

    In plain wordsIn mice, degarelix decreased circulating testosterone, as did the other androgen deprivation methods.

    Peptide
    Degarelix
    Outcome
    DecreaseCirculating testosterone
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    All 3 modes of ADT decreased circulating testosterone levels in mice, although leuprolide treatment reached nadir levels of testosterone later.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, leuprolide decreased circulating testosterone, as did the other androgen deprivation modalities.

    In plain wordsIn mice, leuprolide reduced testosterone but reached its lowest level later than the other androgen deprivation methods.

    Peptide
    Leuprolide
    Outcome
    DecreaseCirculating testosterone
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    All 3 modes of ADT decreased circulating testosterone levels in mice, although leuprolide treatment reached nadir levels of testosterone later.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, degarelix produced less visceral fat gain than orchiectomy.

    In plain wordsIn mice, degarelix produced less visceral fat gain than orchiectomy.

    Peptide
    Degarelix
    Outcome
    DecreaseVisceral fat accumulation
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Orchiectomy
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Orchiectomized and leuprolide-treated mice gained significantly more visceral fat compared with degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, degarelix produced less visceral fat gain than leuprolide.

    In plain wordsIn mice, degarelix produced less visceral fat gain than leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseVisceral fat accumulation
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Leuprolide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Orchiectomized and leuprolide-treated mice gained significantly more visceral fat compared with degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, leuprolide produced significantly more visceral fat gain than degarelix.

    In plain wordsIn mice, leuprolide produced significantly more visceral fat gain than degarelix.

    Peptide
    Leuprolide
    Outcome
    IncreaseVisceral fat accumulation
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Degarelix
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Orchiectomized and leuprolide-treated mice gained significantly more visceral fat compared with degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, improved glucose tolerance tests were recorded with degarelix.

    In plain wordsIn mice, improved glucose tolerance tests were recorded with degarelix.

    Peptide
    Degarelix
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Improved glucose tolerance tests were recorded in degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, leuprolide increased aortic atherosclerotic plaque area versus control (P<0.005).

    In plain wordsIn mice, leuprolide increased aortic plaque area versus control.

    Peptide
    Leuprolide
    Outcome
    IncreaseAortic atherosclerotic plaque area
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Sham surgery plus vehicle
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The aortic atherosclerotic plaque area in leuprolide-treated and orchiectomized mice was larger than in control mice (P<0.005 and P = 0.002, respectively), but it was not significantly different from control in degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, aortic plaque area with degarelix did not differ significantly from control.

    In plain wordsIn mice, aortic plaque area with degarelix did not differ significantly from control.

    Peptide
    Degarelix
    Outcome
    No significant changeAortic atherosclerotic plaque area
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Sham surgery plus vehicle
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The aortic atherosclerotic plaque area in leuprolide-treated and orchiectomized mice was larger than in control mice (P<0.005 and P = 0.002, respectively), but it was not significantly different from control in degarelix-treated mice.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, degarelix reduced plaque necrotic core area versus leuprolide (P = 0.011).

    In plain wordsIn mice, degarelix reduced plaque necrotic core area versus leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreasePlaque necrotic core area
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Leuprolide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The necrotic core area in degarelix-treated mice was smaller compared with leuprolide-treated and orchiectomized mice (P = 0.011 and P = 0.002, respectively).
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice, degarelix reduced plaque necrotic core area versus orchiectomy (P = 0.002).

    In plain wordsIn mice, degarelix reduced plaque necrotic core area versus orchiectomy.

    Peptide
    Degarelix
    Outcome
    DecreasePlaque necrotic core area
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Orchiectomy
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The necrotic core area in degarelix-treated mice was smaller compared with leuprolide-treated and orchiectomized mice (P = 0.011 and P = 0.002, respectively).
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice, plaque necrotic core area was larger with leuprolide than degarelix (P = 0.011).

    In plain wordsIn mice, plaque necrotic core area was larger with leuprolide than degarelix.

    Peptide
    Leuprolide
    Outcome
    IncreasePlaque necrotic core area
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Degarelix
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    The necrotic core area in degarelix-treated mice was smaller compared with leuprolide-treated and orchiectomized mice (P = 0.011 and P = 0.002, respectively).
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice, leuprolide reached testosterone nadir later than degarelix and orchiectomy.

    In plain wordsIn mice, testosterone reached its lowest level later with leuprolide than with degarelix or surgical castration.

    Peptide
    Leuprolide
    Outcome
    IncreaseTime to testosterone nadir
    Study

    mousen: not reported in source

    Low-density lipoprotein receptor knockout mice
    Comparator
    Degarelix and orchiectomy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 4 monthsAs given in this study (mouse).

    Source sentences

    Summary
    All 3 modes of ADT decreased circulating testosterone levels in mice, although leuprolide treatment reached nadir levels of testosterone later.
    1 context sentence
    Summary · context
    Low-density lipoprotein receptor knockout mice underwent orchiectomy plus vehicle (2.5% mannitol), sham surgery plus vehicle (control), sham surgery plus gonadotropin-releasing hormone (GnRH) antagonist (degarelix), or sham surgery plus GnRH agonist (leuprolide) (n = 9-13/group) and were followed for 4 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.